News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

April 2, 2012

Announcement regarding the Filing in Japan of
an Application for Marketing Approval of KW-6002 for
Parkinson's Disease Treatment

Tokyo, Japan, April 2, 2012 --- Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") announces that it will submit on the application in Japan for the marketing approval of KW-6002 (Istradefylline), which is currently undergoing development for the treatment of Parkinson's disease, has been submitted on March 30, 2012.

KW-6002 is a selective antagonist of adenosine A2A receptors. Kyowa Hakko Kirin has been developing KW-6002 as anti-Parkinson's disease drug with a novel mechanism of action. The outcomes from Japanese clinical trials conducted so far have demonstrated the efficacy and tolerability of KW-6002 in Parkinson's disease patients receiving levodopa therapy.

Kyowa Hakko Kirin believes that KW-6002 provides a new treatment option that is potentially useful in the treatment of Parkinson's disease.



To Page Top